Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12633541

Direct stenting.

Emanuele Barbato·Jean Marco·William Wijns
View original source ↗Export metadata ↓

Abstract

Stents have ameliorated the outcome of percutaneous coronary interventions. Improved design, profile and flexibility of the currently available stents now permit to deliver the stent without pre-dilatation. In western European countries, stent implantation now occurs in up to 80% of all percutaneous revascularization procedures. In selected cases the safety and feasibility of direct stenting over conventional balloon-predilatation stenting has been demonstrated, in association with slightly superior outcome. This likely results from reduced vessel wall damage-dissections are sealed at the moment they are created-and distal embolization is reduced. In addition, a significant reduction in terms of costs and duration of procedures was demonstrated, while restenosis rate is not reduced with direct stenting.

Explore related subjects

Angioplasty, Balloon, CoronaryCoronary RestenosisCoronary StenosisCosts and Cost AnalysisHumansMyocardial RevascularizationStentsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Emanuele Barbato, Jean Marco, William Wijns. 2003. Direct stenting.. https://doi.org/10.1016/s0195-668x(02)00802-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Candidate genetic markers and the risk of restenosis after coronary angioplasty.

The aim of the present study was to test for possible associations between candidate gene polymorphisms and the risk of restenosis and recurrent restenosis after percutaneous transluminal coronary angioplasty (PTCA) without stenting. We followed up 511 PTCA patients, and restenosis and recurrent restenosis were defined according to angiographical criteria. Genotyping of the beta-fibrinogen -455 G/A, glycoprotein (GP) IIIa PlA1/PlA2, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, factor V Leiden 1691 G/A, tumour necrosis factor alpha (TNFalpha) -238 G/A, TNFalpha -308 G/A, interleukin (IL)-1alpha -889 C/T, IL-1beta -511 C/T, methylenetetrahydrofolate reductase (MTHFR) 677 C/T and endothelial nitric oxide synthase (eNOS) 4 b/a gene polymorphisms was performed by PCR and restriction-fragment-length-polymorphism-based techniques. One hundred and sixty patients (31.3%) developed restenosis and in 130 of these patients, of whom 123 were available for analysis, a second PTCA without stenting was performed. Of these patients, 35 (28.5%) developed recurrent restenosis. None of the investigated genotypes were associated with the risk of restenosis or recurrent restenosis after PTCA. The degree of stenosis before and immediately after PTCA and the severity of the lesion were independent predictors for restenosis after PTCA. In conclusion, there was no association between the beta-fibrinogen -455 G/A, GP IIIa PlA1/A2, PAI-1 4G/5G, factor V Leiden 1691 G/A, TNFalpha -238 G/A, TNFalpha -308 G/A, IL-1alpha -889 C/T, the IL-1beta -511 C/T, MTHFR 677 C/T and eNOS 4 b/a gene polymorphisms and the risk of restenosis after PTCA as well as recurrent restenosis after repeated PTCA.

Angioplasty, Balloon, Coronary↗
PubMed2004

Genetic risk markers for post-angioplasty restenosis: what should we expect?

Genetic risk markers for coronary artery disease and associated phenotypes, such as restenosis after angioplasty, have the potential to be valuable to the individual, but even more so in facilitating an understanding of causal factors in the disease, and thereby the development of novel preventative and therapeutic strategies. In this issue of Clinical Science, Völzke and co-workers were unable to show association of a panel of candidate polymorphisms with restenosis, but their study has highlighted the need for even larger studies, as well as the potential benefits of finding causal genetic variation.

Angioplasty, Balloon, Coronary↗